

consumer complaint because it contained personal information, but would act to protect the information from disclosure in litigation or otherwise, then the Bureau Director must obtain assurances that the receiving agency will act to protect the information as well.

The Bureau Directors' authority under this delegation may be redelegated. Prior to disclosing consumer complaints to foreign governments under the foregoing delegation, the Bureau Director shall, unless the disclosure is needed to obtain information in a pending Commission investigation, transmit a proposed letter providing for such disclosure to the Secretary and the Secretary shall notify the Commission of the proposed disclosure. If no Commissioner objects to the proposed disclosure within three days following the Commission's receipt of such notification, the Secretary shall inform the Bureau Director that he or she may proceed with the disclosure.

Effective Date: March 14, 1997.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 97-8063 Filed 3-28-97; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Antiterrorism and Effective Death Penalty Act of 1996; Delegation of Authority

Notice is hereby given that I have delegated to the Director, Centers for Disease Control and Prevention, with authority to redelegate, all the authorities vested in the Secretary of Health and Human Services under Section 511—Enhanced Penalties and Biological Agents (42 U.S.C. 262), of the Antiterrorism and Effective Death Penalty Act of 1996 (Public Law 104-132), as amended hereafter. This delegation excludes the authority to promulgate regulations and to submit reports to the Congress.

This delegation became effective upon date of signature. In addition, I have affirmed and ratified any actions taken by the Director, Centers for Disease Control and Prevention or his subordinates which, in effect, involved the exercise of the authorities delegated herein prior to the effective date of the delegation.

Dated: March 18, 1997.

Donna E. Shalala,

Secretary.

[FR Doc. 97-7988 Filed 3-28-97; 8:45 am]

BILLING CODE 4160-18-M

Food and Drug Administration

Docket No. 97N-0117

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the collection of information on a medicated feed mill license application form (form FDA 3448). FDA is also announcing that this collection of information has been submitted to the Office of Management and Budget (OMB) for emergency processing and that OMB has approved the information collection through June 30, 1997, under OMB control number 0910-0337.

DATES: Submit written comments on the collection of information by May 30, 1997.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B-19, Rockville, MD 20857, 301-827-1472.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the

public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information before submitting the collection to OMB for approval. FDA is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Medicated Feed Mill License Application, Form FDA 3448 (OMB Control Number 0910-0337)

The Animal Drug Availability Act (the ADAA) of 1996 (Pub. L. 104-250), which amended section 512(a) and (m) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b(a) and (m)), mandates that FDA replace the system for the approval of specific medicated feeds with a general licensing system. The ADAA reduced the paperwork necessary to gain approval to manufacture medicated feeds. Before passage of the ADAA, medicated feed manufacturers were required to obtain approved Medicated Feed Applications (MFA's) in order to manufacture certain types of medicated feeds. A separate approved MFA was required for each and every applicable medicated feed.

Now, under section 512(a) and (m) of the act as amended by the ADAA, each feed manufacturing facility need submit only one feed mill license application to FDA for the manufacture of medicated feeds. In order to be licensed in accordance with the criteria of section 512(m)(1), a feed manufacturer must, among other things, provide a full statement of the business name, address, and registration number of the feed manufacturing facility and the name and signature of the responsible individual for that facility. To implement these requirements, FDA's medicated feed mill license application

form will request the following information of each applicant: (1) Manufacturing site legal business name; (2) Address; (3) Phone number; (4) FAX number; (5) Type of application; (6) FDA registration number; and (7) Date and signature.

The information on the form will be used to issue medicated feed mill licenses. The information requested on

the form is specifically mandated by the ADAA, except for the telephone and fax numbers. These numbers are needed so that FDA can contact the firm quickly when necessary. The additional burden of supplying this information is minimal. The likely respondents are feed manufacturing facilities.

FDA intends as soon as possible to issue a proposed rule that incorporates

the statutory feed mill licensing provisions. FDA does not anticipate that the proposed collection of information set forth in the proposed rule will differ from the proposed collection of information set forth above.

FDA estimates the burden of this collection of information as follows:

ESTIMATED ANNUAL REPORTING BURDEN: FIRST YEAR

Federal Food, Drug, and Cosmetic Act	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
512(m)(1)	2,000	1	2,000	0.25	500

There are no capital costs or operating and maintenance costs associated with this collection of information.

ESTIMATED ANNUAL REPORTING BURDEN: EACH SUCCEEDING YEAR

Federal Food, Drug, and Cosmetic Act	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
512(m)(1)	100	1	100	0.25	25

There are no capital costs or operating and maintenance costs associated with this collection of information.

FDA estimates 2,000 respondents within the first year based on the number of current MFA holders (approximately 2,000). Furthermore, FDA estimates 100 respondents for each succeeding year based on the average number of new firms that began to manufacture medicated feed in past years.

Dated: March 25, 1997.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 97-8047 Filed 3-28-97; 8:45 am]

BILLING CODE 4160-01-F

Health Care Financing Administration [ORD-097-N]

New and Pending Demonstration Project Proposals Submitted Pursuant to Section 1115(a) of the Social Security Act: January 1997 and Supplement to December 1996 Listing

AGENCY: Health Care Financing Administration (HCFA).

ACTION: Notice.

SUMMARY: This notice identifies proposals that were submitted under the authority of section 1115 of the Social Security Act during the month of January 1997. No proposals were approved, disapproved, or withdrawn during this time period. The notice also identifies pending proposals for the month of January 1997. In addition, it also identifies an additional proposal

received in December 1996 that we inadvertently omitted in the December listing. (This notice can be accessed on the Internet at [HTTP://WWW.HCFA.GOV/ORD/ORDHP1.HTML](http://WWW.HCFA.GOV/ORD/ORDHP1.HTML).)

COMMENTS: We will accept written comments on these proposals. We will, if feasible, acknowledge receipt of all comments, but we will not provide written responses to comments. We will, however, neither approve nor disapprove any new proposal for at least 30 days after the date of this notice to allow time to receive and consider comments. Direct comments as indicated below.

ADDRESSES: *Mail correspondence to:* Susan Anderson, Office of Research and Demonstrations, Health Care Financing Administration, Mail Stop C3-11-07, 7500 Security Boulevard, Baltimore, MD 21244-1850.

FOR FURTHER INFORMATION CONTACT: Susan Anderson, (410) 786-3996.

SUPPLEMENTARY INFORMATION:

I. Background

Under section 1115 of the Social Security Act (the Act), the Department of Health and Human Services (HHS) may consider and approve research and demonstration proposals with a broad range of policy objectives. These demonstrations can lead to improvements in achieving the purposes of the Act.

In exercising her discretionary authority, the Secretary has developed a

number of policies and procedures for reviewing proposals. On September 27, 1994, we published a notice in the **Federal Register** (59 FR 49249) that specified (1) the principles that we ordinarily will consider when approving or disapproving demonstration projects under the authority in section 1115(a) of the Act; (2) the procedures we expect States to use in involving the public in the development of proposed demonstration projects under section 1115; and (3) the procedures we ordinarily will follow in reviewing demonstration proposals. We are committed to a thorough and expeditious review of State requests to conduct such demonstrations.

As part of our procedures, we publish a notice in the **Federal Register** with a monthly listing of all new submissions, pending proposals, approvals, disapprovals, and withdrawn proposals. Proposals submitted in response to a grant solicitation or other competitive process are reported as received during the month that such grant or bid is awarded, so as to prevent interference with the awards process.

II. Supplement to December 1996 Listing of New Proposals

In the December 1996 listing published in the **Federal Register** (62 FR 8451), under Section II. Other Section 1115 Demonstration Proposals, we inadvertently omitted the following new proposal: